APA (7th ed.) Citation

F, N., J, H., P, d. R., E, P., L, C., A, M., . . . L, M. (2025). Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials. NPJ precision oncology, 10(1), 38. https://doi.org/10.1038/s41698-025-01231-x

Chicago Style (17th ed.) Citation

F, Nichetti, et al. "Benchmarking Progression-free Survival Ratio as Primary Endpoint in Precision Oncology Clinical Trials." NPJ Precision Oncology 10, no. 1 (2025): 38. https://doi.org/10.1038/s41698-025-01231-x.

MLA (9th ed.) Citation

F, Nichetti, et al. "Benchmarking Progression-free Survival Ratio as Primary Endpoint in Precision Oncology Clinical Trials." NPJ Precision Oncology, vol. 10, no. 1, 2025, p. 38, https://doi.org/10.1038/s41698-025-01231-x.